Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / deadline alert for btai mnk and stx the law offices mwn benzinga


STX - DEADLINE ALERT for BTAI MNK and STX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders | Benzinga

  • LOS ANGELES, Sept. 05, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion.

    Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to fcruz@frankcruzlaw.com.

    BioXcel Therapeutics, Inc. (NASDAQ:BTAI)
    Class Period: December 15, 2021 – June 28, 2023
    Lead Plaintiff Deadline: September 5, 2023

    The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company lacked adequate internal controls over protocol adherence and data integrity; (2) that, as a result, the Company's principal investigator failed to adhere to the informed consent form approved by the Institutional Review Board; (3) that the Company's principal investigator failed to maintain adequate case histories for certain patients whose records were reviewed by the FDA; (4) that the Company's principal investigator fabricated email correspondence with a pharmacovigilance safety vendor that was then provided to the FDA; (5) that the foregoing would negatively impact the Company's ability to obtain regulatory approval of BXCL501 for the treatment of agitation associated with dementia in patients with probable Alzheimer's disease; and (6) that, as a result of the ...

    Full story available on Benzinga.com

  • Stock Information

    Company Name: Seagate Technology Holdings PLC
    Stock Symbol: STX
    Market: NASDAQ

    Menu

    STX STX Quote STX Short STX News STX Articles STX Message Board
    Get STX Alerts

    News, Short Squeeze, Breakout and More Instantly...